Company logo

ALLO - Allogene Therapeutics, Inc.

NASDAQ -> Healthcare -> Biotechnology
South San Francisco, United States

ALLO price evolution
ALLO
Balance Sheet
(in millions $) 30 Jun 2021 31 Mar 2021 31 Dec 2020 30 Sep 2020
Current assets
Cash $232.95 $246.31 $192.8 $167.59
Short term investments $364.2 $462.72 $644.56 $682.89
Net receivables
Inventory
Total current assets $602.17 $716.06 $845.13 $854.06
Long term investments $344.34 $283.92 $207.95 $212.51
Property, plant & equipment $164.93 $163.34 $160.13 $144.21
Goodwill & intangible assets
Total noncurrent assets $524.55 $462.98 $382.7 $368.44
Total investments $708.55 $746.64 $852.5 $895.39
Total assets $1126.72 $1179.04 $1227.83 $1222.5
Current liabilities
Accounts payable $11.01 $14.88 $10.39 $10.15
Deferred revenue $0.3 $0.24 $38.99
Short long term debt
Total current liabilities $46 $54.85 $94.32 $50.13
Long term debt $51.21 $51.63
Total noncurrent liabilities $56.91 $54.42 $53.89 $53.64
Total debt $51.21 $51.63
Total liabilities $102.91 $109.27 $148.21 $103.77
Shareholders' equity
Retained earnings -$750.29 -$679.36 -$646.34 -$577.77
Other shareholder equity -$0.33 -$0.1 $0.27 $0.95
Total shareholder equity $1023.81 $1069.78 $1079.62 $1118.73
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018 31 Dec 2017
Current assets
Cash $192.8 $179.43 $93.73
Short term investments $644.56 $355.41 $366.95
Net receivables
Inventory
Total current assets $845.13 $544.58 $467.98
Long term investments $207.95 $63.21 $261.97
Property, plant & equipment $160.13 $100.94 $41.61
Goodwill & intangible assets $0.15 $0.75
Total noncurrent assets $382.7 $173.23 $305.87
Total investments $852.5 $418.62 $628.92
Total assets $1227.83 $717.8 $773.86
Current liabilities
Accounts payable $10.39 $9.25 $12.34
Deferred revenue $38.99
Short long term debt
Total current liabilities $94.32 $33.08 $29.46 $0
Long term debt $51.35 $34.46
Total noncurrent liabilities $53.89 $55.7 $41.23
Total debt
Total liabilities $148.21 $88.78 $70.69 $0
Shareholders' equity
Retained earnings -$646.34 -$396.12 -$211.53 -$0.02
Other shareholder equity $0.27 $1.15 $0.31 -$0.01
Total shareholder equity $1079.62 $629.02 $703.16
Income Statement
(in millions $) 30 Jun 2021 31 Mar 2021 31 Dec 2020 30 Sep 2020
Revenue
Total revenue $0.04 $38.34
Cost of revenue
Gross Profit $0.04 $38.34
Operating activities
Research & development $52.29 $55.18 $52.23 $51.42
Selling, general & administrative $18.78 $16.36 $17.13 $16.62
Total operating expenses $71.07 $71.55 $69.36 $68.04
Operating income -$71.03 -$33.2 -$69.36 -$68.04
Income from continuing operations
EBIT -$70.94 -$33.02 -$68.57 -$66.2
Income tax expense
Interest expense
Net income
Net income -$70.94 -$33.02 -$68.57 -$66.2
Income (for common shares) -$70.94 -$33.02 -$68.57 -$66.2
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018 31 Dec 2017
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $192.99 $144.53 $151.86
Selling, general & administrative $65.26 $57.47 $40.98
Total operating expenses $258.24 $202.01 $192.84
Operating income -$258.24 -$202.01 -$192.84
Income from continuing operations
EBIT -$250.22 -$184.93 -$208.26
Income tax expense -$0.33 -$0.12
Interest expense $3.36
Net income
Net income -$250.22 -$184.59 -$211.5
Income (for common shares) -$250.22 -$184.59 -$211.5
Cash Flow
(in millions $) 30 Jun 2021 31 Mar 2021 31 Dec 2020 30 Sep 2020
Net income -$70.94 -$33.02 -$68.57 -$66.2
Operating activities
Depreciation $1.96 $1.92 $1.84 $1.81
Business acquisitions & disposals
Stock-based compensation $21.13 $16.79 $16.45 $17.82
Total cash flows from operations -$41.17 -$49.33 -$9.97 -$37.59
Investing activities
Capital expenditures -$10.9 -$6.46 -$17.4 -$20.25
Investments $35.5 $103.26 $39.61 -$63.11
Total cash flows from investing $24.59 $96.8 $22.21 -$83.36
Financing activities
Dividends paid
Sale and purchase of stock $3.21 $6.04 $12.98 $3.85
Net borrowings
Total cash flows from financing $3.21 $6.04 $12.98 $3.85
Effect of exchange rate
Change in cash and equivalents -$13.36 $53.51 $25.21 -$117.09
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018 31 Dec 2017
Net income -$250.22 -$184.59 -$211.5
Operating activities
Depreciation $7.43 $4.42 $1.05
Business acquisitions & disposals -$2.1
Stock-based compensation $65.26 $46.06 $18.57
Total cash flows from operations -$115.09 -$137.35 -$44.65
Investing activities
Capital expenditures -$65.96 -$50.79 -$3.23
Investments -$439.17 $214.88 -$627.47
Total cash flows from investing -$505.12 $164.08 -$632.8
Financing activities
Dividends paid
Sale and purchase of stock $633.59 $58.96 $355.06
Net borrowings $116.84
Total cash flows from financing $633.59 $58.96 $771.18
Effect of exchange rate
Change in cash and equivalents $13.38 $85.69 $93.73
Fundamentals
Market cap $2.44B
Enterprise value $2.26B
Shares outstanding 142.18M
Revenue $38.39M
EBITDA -$231.18M
EBIT -$238.72M
Net Income -$238.72M
Revenue Q/Q InfinityT%
Revenue Y/Y N/A
P/E ratio -10.23
EV/Sales 58.86
EV/EBITDA -9.77
EV/EBIT -9.47
P/S ratio 63.59
P/B ratio 2.38
Book/Share 7.20
Cash/Share 1.64
EPS -$1.68
ROA -20.08%
ROE -22.25%
Debt/Equity 0.14
Net debt/EBITDA 0.56
Current ratio 13.09
Quick ratio 13.09